Precision oncology strategy in trastuzumab-resistant human epidermal growth factor receptor 2-positive colon cancer: Case report of durable response to ado-trastuzumab emtansine

JCO Precision Oncology

Volumn 2017, Issue 1, 2017, Pages 1-6

  Haslem, Derrick S ^a   Ji, Hanlee P ^b   Ford, James M ^b   Nadauld, Lincoln D ^a,b  

^a Dixie Regional Medical Center   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IRINOTECAN; OXALIPLATIN; REGORAFENIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ADRENAL METASTASIS; ADULT; ARTICLE; CASE REPORT; CLINICAL ARTICLE; COLON CANCER; DRUG RESPONSE; DRUG WITHDRAWAL; FLANK PAIN; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KRAS GENE; LUNG METASTASIS; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RECTUM HEMORRHAGE; SIDE EFFECT; TREATMENT DURATION; X-RAY COMPUTED TOMOGRAPHY;

EID: 85047602514     PISSN: None     EISSN: 24734284     Source Type: Journal    
DOI: 10.1200/PO.16.00055     Document Type: Article

References (26)

1. Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006
2. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
3. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
4. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer.NEngl J Med 357: 2040-2048, 2007
5. Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 28:4697-4705, 2010
6. Nadauld LD, Ford JM: Molecular profiling of gastric cancer: Toward personalized cancer medicine. J Clin Oncol 31: 838-839, 2013
7. Coussens L, Yang-Feng TL, Liao YC, et al: Tyrosine kinase receptor with extensive homology toEGFreceptor shares chromosomal location with neu oncogene. Science 230:1132-1139, 1985
8. Slamon DJ, ClarkGM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
9. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
10. Sartore-Bianchi A, Trusolino L, Martino C, et al: Dual-targeted therapy with trastuzumab and lapatinib in treatmentrefractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-ofconcept, multicentre, open-label, phase 2 trial. Lancet Oncol 17:738-746, 2016
11. Hainsworth JD, Meric-Bernstam F, Swanton C, et al: Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study. J Clin Oncol 34, 2016 (suppl; abstr LBA11511)
12. Valtorta E, Martino C, Sartore-Bianchi A, et al: Assessment of a HER2 scoring system for colorectal cancer: Results from a validation study. Mod Pathol 28:1481-1491, 2015
13. Richman SD, Southward K, Chambers P, et al: HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: Analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol 238:562-570, 2016
14. Sartore-Bianchi A, Ardini E, Bosotti R, et al: Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer. J Natl Cancer Inst 108, 2015
15. Amatu A, Somaschini A, Cerea G, et al: Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. Br J Cancer 113:1730-1734, 2015
16. Sparks AB, Morin PJ, Vogelstein B, et al: Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 58:1130-1134, 1998
17. Nigro JM, Baker SJ, Preisinger AC, et al: Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708, 1989
18. Baker SJ, Fearon ER, Nigro JM, et al: Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217-221, 1989
19. Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330-337, 2012
20. Bertotti A, Migliardi G, Galimi F, et al: A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 1:508-523, 2011
21. Parikh A, Atreya C, Korn WM, et al: Prolonged response to HER2-directed therapy in a patient with HER2-amplified, rapidly progressive metastatic colorectal cancer. J Natl Compr Canc Netw 15:3-8, 2017
22. Kavuri SM, Jain N, Galimi F, et al: HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov 5:832-841, 2015
23. Bensch F, van Rooijen JM, Schröder CP, et al: A 21-year-old patient with a HER2-positive colorectal cancer. Gastroenterology 148:20-21, 2015
24. Sorscher SM: Marked response to single agent trastuzumab in a patient with metastatic HER-2 gene amplified rectal cancer. Cancer Invest 29:456-459, 2011
25. Grothey A, Van Cutsem E, Sobrero A, et al: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381: 303-312, 2013
26. Roychowdhury S, Iyer MK, Robinson DR, et al: Personalized oncology through integrative high-throughput sequencing: A pilot study. Sci Transl Med 3:111ra121, 2011